Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Cash from Investing Activities: 2016-2024

Historic Cash from Investing Activities for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Dec 2024 value amounting to -$574.8 million.

  • Crinetics Pharmaceuticals' Cash from Investing Activities rose 699.93% to $164.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$425.3 million, marking a year-over-year decrease of 254.30%. This contributed to the annual value of -$574.8 million for FY2024, which is 186.82% down from last year.
  • Per Crinetics Pharmaceuticals' latest filing, its Cash from Investing Activities stood at -$574.8 million for FY2024, which was down 186.82% from -$200.4 million recorded in FY2023.
  • Crinetics Pharmaceuticals' Cash from Investing Activities' 5-year high stood at $217,000 during FY2020, with a 5-year trough of -$574.8 million in FY2024.
  • Over the past 3 years, Crinetics Pharmaceuticals' median Cash from Investing Activities value was -$200.4 million (recorded in 2023), while the average stood at -$316.4 million.
  • Data for Crinetics Pharmaceuticals' Cash from Investing Activities shows a maximum YoY slumped of 26,129.03% (in 2021) over the last 5 years.
  • Over the past 5 years, Crinetics Pharmaceuticals' Cash from Investing Activities (Yearly) stood at $217,000 in 2020, then slumped by 26,129.03% to -$56.5 million in 2021, then tumbled by 208.02% to -$174.0 million in 2022, then dropped by 15.19% to -$200.4 million in 2023, then slumped by 186.82% to -$574.8 million in 2024.